1. Home
  2. CTSO vs FMY Comparison

CTSO vs FMY Comparison

Compare CTSO & FMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cytosorbents Corporation

CTSO

Cytosorbents Corporation

N/A

Current Price

$0.73

Market Cap

45.7M

Sector

Health Care

ML Signal

N/A

Logo First Trust Motgage Income Fund of Beneficial Interest

FMY

First Trust Motgage Income Fund of Beneficial Interest

N/A

Current Price

$11.75

Market Cap

51.7M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
CTSO
FMY
Founded
1997
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
45.7M
51.7M
IPO Year
2008
N/A

Fundamental Metrics

Financial Performance
Metric
CTSO
FMY
Price
$0.73
$11.75
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$5.38
N/A
AVG Volume (30 Days)
67.1K
7.1K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
6.98%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$22,503,908.00
N/A
Revenue This Year
$7.29
N/A
Revenue Next Year
$8.91
N/A
P/E Ratio
N/A
N/A
Revenue Growth
48.53
N/A
52 Week Low
$0.60
$11.65
52 Week High
$1.39
$12.39

Technical Indicators

Market Signals
Indicator
CTSO
FMY
Relative Strength Index (RSI) 54.78 35.26
Support Level $0.62 N/A
Resistance Level $0.84 $12.34
Average True Range (ATR) 0.04 0.10
MACD 0.01 -0.04
Stochastic Oscillator 59.46 9.23

Price Performance

Historical Comparison
CTSO
FMY

About CTSO Cytosorbents Corporation

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

About FMY First Trust Motgage Income Fund of Beneficial Interest

First Trust Mortgage Income Fund is a United States-based diversified, closed-end management investment company. The fund's primary investment objective is to seek a high level of current income. Its secondary investment objective is to preserve capital. The fund pursues its objectives by investing predominantly in mortgage-backed securities representing part ownership in a pool of either residential or commercial mortgage loans that, in the opinion of the Fund's investment advisor, offer an attractive combination of credit quality, yield, and maturity.

Share on Social Networks: